Every day matters. Why wait?

About the Test


With the rise of precision oncology, genomic profiling is playing an increasingly large role in clinical decision making and bringing clarity to targeted treatment approaches. Across all advanced cancer types, faster answers are needed.


Explore the benefits of the Oncotype MAP test


Oncotype MAP packaging


The Oncotype MAP Pan-Cancer Tissue Test delivers rapid, comprehensive tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer. The test identifies actionable genomic alterations within 3-5 business days to guide timely treatment decisions, usually before the next follow up visit.

Utilizing next generation sequencing (NGS) and a broad array of immunohistochemical (IHC) stains and panels, the Oncotype MAP Pan-Cancer Tissue Test identifies clinically-relevant genomic alterations from patient specimens as small as 3 mm2 of tissue or 2-3 slides‡. Fewer Quantity Not Sufficient (QNS) samples mean more of your patients get tested and treated.


REQUEST INFORMATION

Why Oncotype MAP Pan-Cancer Tissue Test?



FAST

icon fast

  • Results in 3-5 business days
  • Quantity Not Sufficient (QNS) results typically reported within 48 hours


    • COMPREHENSIVE

    icon comprehensive

  • >250 genes, 11 fusions
  • 22 IHC stains
  • 25+ disease specific panels
  • Copy number variants
  • Tumor mutation burden
  • Protein expression


    • ACTIONABLE

    icon actionable

    Test assesses:
  • 100+ therapies
  • 45+ combination therapies
  • 650+ clinical trials


    • ACCURATE

    icon accurate

  • FNA and FFPE samples as small as 3 mm2 with ≥15% tumor content
  • >99% sensitivity for SNVs and Indels, detection down to ≥7.5% mutant allele frequency (MAF) with >99% specificity*



    • Actionable Indications for Therapies and Clinical Trials


    Results are provided in an easy-to-interpret report with NCCN actionable indications for therapy, along with potential evidence-based therapies and clinical trials, to deliver treatment options for a breadth of solid tumor types.


    EXPLORE SAMPLE REPORT



    Download Sample Report PDF


    Comprehensive List of Genes and IHC Panels


    The Oncotype MAP Pan-Cancer Tissue Test profiles a wide range of genetic structures including:

    • Single nucleotide variants (SNVs) and insertions/deletions in coding regions of the genes listed below
    • Untranslated regions (UTRs) and splice junctions when actionable, e.g. MET exon 14 skipping and EGFRvIII
    • Microsatellite instability (MSI)
    • Tumor mutational burden (SNVs, insertions, deletions) based on -1 megabase
    • Select fusions involving ALK, BRAF, FGFR1, FGFR2, FGFR3, MET, RET, ROS1, NTRK1, NTRK2, NTRK3 (ETV6)
    • Copy number variants


    VIEW 257 NGS GENE PANEL
    257 NGS Gene Panel
    ABCB1
    ABCC1
    ABCC2
    ABL1
    ACVR1
    ACVR1B
    ACVR2A
    ACVR2B
    ACVRL1
    ADAMTS1
    ADAMTS6
    ADAMTS9
    ADAMTS16
    ADAMTS18
    ADAMTSL1
    AKT1
    AKT2
    AKT3
    ALK
    AMER1
    APC
    APLNR
    AR
    ARAF     		AREG
    ARID1A
    ARID1B
    ARID2
    ATM
    ATR
    ATRX
    AURKA
    AURKB
    AXIN1
    AXL
    B2M
    BAP1
    BARD1
    BCOR
    BMP6
    BMPR1A
    BMPR1B
    BNIP3
    BRAF
    BRCA1
    BRCA2
    BRIP1
    BTK     		BUB1B
    CALR
    CBL
    CCND1
    CCND2
    CCND3
    CCNE1
    CD274
    CDA
    CDC73
    CDH1
    CDK4
    CKD6
    CDK12
    CDKN2A
    CHEK1
    CHEK2
    CHFR
    CHKA
    CIC
    CREBBP
    CSF1R
    CTLA4
    CTNNB1     		CYP19A1
    CYP1A1
    CYP2D6
    CYP3A4
    CYSLTR2
    DCK
    DDR2
    DICER1
    DNMT3A
    EGFR
    EMSY
    EP300
    EPCAM
    EPHA5
    EPHA7
    ERBB2
    ERBB3
    ERBB4
    ERCC1
    ERCC2
    ERCC3
    ERRFI1
    ESR1
    ESR2     		EWSR1
    EZH2
    FAM175A
    FANCA
    FANCC
    FANCD2
    FANCE
    FANCF
    FANCG
    FANCM
    FAT1
    FBXW7
    FCGR2A
    FGD4
    FGF3
    FGF4
    FGFR1
    FGFR2
    FGFR3
    FGFR4
    FLT3
    FLT4
    FOXL2
    FUBP1     		GAS6
    GATA3
    GLI1
    GNA11
    GNAQ
    GNAS
    GSTP1
    HAMP
    HDAC2
    HGF
    HNF1A
    HRAS
    HSD3B1
    IDH1
    IDH2
    IGF1R
    IKZF1
    IL6R
    JAK1
    JAK2
    JAK3
    KDM5C
    KDM6A
    KDR     		KEAP1
    KIT
    KRAS
    MAF
    MAP2K1
    MAP2K2
    MAP3K1
    MAPK1
    MAPK3
    MAPKAPK5
    MDM2
    MDM4
    MED12
    MEN1
    MET
    MGMT
    MLH1
    MPL
    MRE11A
    MSH2
    MSH6
    MTHFR
    MTOR
    MUTYH     		MYC
    MYCN
    MYOD1
    NBN
    NF1
    NF2
    NFE2L2
    NOTCH1
    NOTCH2
    NOTCH3
    NPMI
    NRAS
    NTRK1
    NTRK2
    NTRK3
    PALB2
    PBRM1
    PDCD1LG2
    PDGFRA
    PDGFRB
    PIK3CA
    PIK3CB
    PIK3CD
    PIK3CG     		PIK3R1
    PIM1
    PLCB4
    PLCG1
    PMS2
    POLD1
    POLE
    PP2R1A
    PTCH1
    PTEN
    PTPN11
    RAD50
    RAD51C
    RAD51D
    RAF1
    RB1
    RBM10
    RECQL
    RET
    RHEB
    RICTOR
    RIT1
    RNF43
    ROS1     		RPTOR
    RRMI
    SDHB
    SDHC
    SETD2
    SF3B1
    SMAD1
    SMAD2
    SMAD4
    SMAD5
    SMAD9
    SMARCA4
    SMARCB1
    SMO
    SOCS1
    SPOP
    STAG2
    STAT3
    STAT5A
    STAT5B
    STK11
    SUFU
    TERT-p
    TGFB1     		TGFB2
    TGFB3
    TGFBR1
    TGFBR2
    TNFA1P3
    TNK1
    TOP2A
    TP53
    TSC1
    TSC2
    TSHR
    TYMS
    VEGFA
    VHL
    WTI
    XRCC1
    YES1
    VIEW SINGLE IHC STAINS -and- TUMOR-SPECIFIC IHC PANELS
    Single IHC Stains
    ALK
    AR
    CAIX
    ER
    hENTI
    HER2
    IDO     		MET
    MGMT
    MLH1
    MMR (4
    IHC)
    MSH2
    MSH6     		PD1
    PD-L1 (22C3)
    PD-L1 (SP142)
    PMS2
    PR
    PTEN
    ROS1     		TOP1
    TP
    TRKpan
    TS
    TUBB3
    Tumor-specific Panels
    Anal Carcinoma: PD-L1 (22C3), PD-1, TS, TUBB3
    Appendix: HER2, PD-L1 (22C3), TOP1, PTEN
    Bladder: PD-L1 (22C3), PD-L1 (SP142), hENTI, TUBB3
    Bone Cancer: TOP1, MGMT, CAIX, HENTI
    Breast: AR, PD-L1(SP142), PD-L1 (22C3), TP
    CNS / Brain Cancers: MGMT, CAIX, TUBB3, TOP1
    Cervical: PD-L1 (22C3), CAIX, hENTI, TOP1
    Colorectal: HER2, PD-L1 (22C3), TOP1, PTEN, TS
    Gastric / Esophageal: HER2, PD-L1 (22C3), PTEN, TS
    GIST: PD-L1 (22C3), MET
    Head and Neck: PD-L1 (22C3), CAIX, TUBB3, PTEN
    Head and Neck Salivary Gland: HER2, AR, CAIX, PTEN
    Hepatobillary / Cholangiocarcinoma: hENTI, HER2, TP, PD-L1 (22C3)
    Hepatobillary / Gallbladder: hENTI, HER2, PD-L1 (22C3), TOP1
    Hepatobillary / Hepatocellular: hENTI, PD-L1 (22C3), CAIX, MET
    Kidney: PD-L1 (22C3), MET, CAIX, hENTI
    Melanoma: PD-L1 (22C3), MGMT, PTEN, TUBB3
    Mesothelioma: PD-L1 (22C3), TS, hENTI, TUBB3
    		MMR: MLH1, MSH2, MSH6, PMS2
    Neuroendocrine: PD-L1 (22C3), MGMT, PTEN, TP
    NSCLC: PD-L1 (22C3), ALK, PD-L1 (SP142), PTEN, TS
    Ovarian: ER, HER2, TOP1, TUBB3
    Pancreatic: hENTI, PTEN, TP, TOP1
    Penile Cancer: PD-L1 (22C3), TP, CAIX, TUBB3
    Prostate: AR, PTEN, TUBB3, PD-L1 (22C3)
    Sarcoma: CAIX, TUBB3, TOP1, MGMT
    SCLC: PD-L1 (22C3), TOP1, MGMT
    Small Bowel: TOPO1, CAIX, TUBB3, hENTI
    Testicular Cancer: PD-L1 (22C3), TUBB3, hENTI
    Thyroid: PD-L1 (22C3), ALK, TUBB3, CAIX
    Thymoma / Thymic Carcinoma: PD-L1 (22C3), TUBB3, hENTI, TS
    Uterine: PD-L1 (22C3), HER2, MGMT, TUBB3
    Uveal Melanoma: PD-L1 (22C3), MGMT, TUBB3
    Vulvar Cancer: PD-L1 (22C3), CAIX, TUBB3, hENTI
    Other Solid Tumors: PD-L1 (22C3), HER2, TOP1, PTEN, TS


    Health Professional Radio Podcast


    Listen to Dr. Rick Baehner, MD, Chief Medical Officer of Precision Oncology at Exact Sciences discuss the Oncotype MAP Pan-Cancer Tissue test and how it provides actionable insights to inform treatment decisions for patients with advanced cancer.


    Oncotype MAP Pan-Cancer Tissue test helps guide therapy selection today and captures emerging clinical trial markers that may find their way into guidelines tomorrow.
    ORDER NOW

    Shipping Instructions


    shipping icon Step 1

    Place the Oncotype MAP Requisition Form, a copy of the pathology report, and relevant patient demographics and insurance materials in the Oncotype MAP Pan-Cancer Tissue Kit.

    shipping icon Step 2

    Place the Oncotype MAP Specimen Kit into the FedEx® Clinical Pak. DO NOT include any patient identifiers on the Specimen Kit.

    shipping icon Step 3

    The airbill is pre-printed with Exact Sciences shipping information for your convenience.
    BE SURE TO MARK SERVICE AS “PRIORITY OVERNIGHT”.

      SHIP TO:
      Exact Sciences
      445 N. 5th Street, Suite 300
      Phoenix, AZ 85004

    shipping icon Step 4

    Seal the Clinical Pak by removing the plastic adhesive protector from the white strip and secure.

    shipping icon Step 5

    Place the package in the designated FedEx pickup location at your site.

    shipping icon Questions?

    Contact Customer Service at 866-ONCOTYPE (662-6897).


    Additional Resources


    Download Test Overview
    Download Test Overview

    Download Specimen Submission Guidelines
    Download Specimen Submission Guidelines

    Download Sample Report
    Download Sample Report

    Download Billing Overview
    Download Billing Overview



    Commitment to Patient Genomic Access


    Exact Sciences is committed to supporting patient access to Oncotype MAP Pan-Cancer tissue test to support patients in making informed decisions about their treatment. Medicare covers Oncotype MAP Pan-Cancer tissue test for qualifying members. Commercial coverage varies by insurance plan and patient benefit level. Exact Sciences strongly encourages patients to contact their insurance carrier to better understand their benefits plan. Regardless of network status, all commercial health plan coverage is pursuant to the applicable health plan’s medical policy and specific patient benefit levels. Exact Sciences offers Financial Assistance if a patient is uninsured or concerned about their ability to pay for the out-of-pocket cost of testing.

    LEARN ABOUT BILLING



    Oncotype MAP Product Updates

    Sign up to receive emails about updates to the new Oncotype MAP Pan-Cancer Tissue test



    REFERENCES

    *Data on File, In-house assay optimization protected by trade-secret/patent regulations
    † Turnaround time is based on qualified sample receipt.
    ‡ Morris S, Subramanian J, Gel E, Runger G, Thompson E, Mallery D, et al. Performance of next-generation sequencing on small tumor specimens and/or low tumor content samples using a commercially available platform. PLoS ONE. (2018); 13(4): e0196556. https://doi.org/10.1371/journal.pone.0196556


     
    I agree to be contacted at the email provided above for marketing purposes and accept the Terms & Conditions. For more information about our privacy practices, please read our Privacy Policy.*

    Stay in Touch

    Have questions? We're here to help.

     Contact Us
    Copyright © 2004- Genomic Health, Inc. All Rights Reserved.
    In the US and certain other jurisdictions, Genomic Health, Oncotype, Oncotype DX, Oncotype IQ, Oncotype MAP, Breast Recurrence Score, Recurrence Score, DCIS Score, Colon Recurrence Score, Genomic Prostate Score, GPS, AR-V7 Nucleus Detect, Pass It On: Until Every Woman Knows, and Making Cancer Care Smarter are trademarks of Genomic Health, Inc. Exact Sciences is a trademark of Exact Sciences Corporation.
    Making cancer care smarter.™
    X

    We may use cookies to improve your experience with our website and to provide you with more relevant content based on your interests. To learn more about what information we collect, how we use it, and how to manage cookies, review our Privacy Policy.